Favourable outcome achieved for chronic DME treatment in Europe

Article

Alimera Sciences has announced a positive outcome of the Decentralized Procedure (DCP) for its intravitreal implant, ILUVIEN, in Europe...

Alimera Sciences has announced a positive outcome of the Decentralized Procedure (DCP) for its intravitreal implant, ILUVIEN, in Europe following the issuance of the Final Assessment report, from several bodies, stating it is approvable.

The fluocinolone acetonide intravitreal implant will be the first sustained release treatment for chronic diabetic macular oedema (DME) available in the European Union. Countries granting the licence of ILUVIEN for the treatment of chronic DME in cases that are not responding to alternative therapies include Austria, France, Germany, Italy, Portugal and Spain.

Dan Myers, president and chief executive officer of Alimera, said, "Achieving a favourable conclusion for ILUVIEN in Europe is a significant milestone and very encouraging for the many patients with this challenging chronic disease. We will continue to work closely with the UK and the Concerned Member States to ensure that ILUVIEN is made available to patients as soon as possible."

The implant works through delivery of sustained sub-microgram levels of fluocinolone acetonide, which is facilitated by the positioning of the implant at the back of the eye, allowing it to synchronize with the natural fluid dynamics. It has been proven in a 36-month clinical trial to improve the best-corrected visual acuity by 15 letters or more of DME patients when compared with a sham group.

According to senior vice president of sales and marketing at Alimera Sciences, David Holland, "An effective, truly long-term treatment option could have a very positive impact on the quality of life for patients with this chronic debilitating disease."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
© 2025 MJH Life Sciences

All rights reserved.